Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Muscle stem cell study ends early — but may pave way for future treatments

NCT ID NCT06077734

Knowledge-focused Sponsor: Maastricht University Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether muscle stem cells (mesoangioblasts) from people with muscle loss due to cancer or aging are healthy enough to be used for future cell therapy. Researchers took small muscle samples and blood from 7 participants and measured how well the cells grew and formed muscle. The study was stopped early, so results are limited, but it helps understand if a person's own stem cells could one day treat muscle wasting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

7 people

The number who actually took part.

Started

Nov 2023

Finished

Feb 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Two study populations are included in this study. The Muscle Impaired Elderly (MIE) are considered elderly who struggle with muscle weakness. MIE is used as a substitute group for sarcopenia as their muscle weakness and daily impairments are confirmed, but confirmation via medical imaging lacks. Sarcopenia is multifactorial and the balance between nutrition and activity is disturbed. Cachexia is defined as an ongoing loss of skeletal muscle mass due to an illness that cannot be reversed by conventional nutrition and/or exercise. Lung cancer cachexia is a group where non-small cell lung cancer is confirmed along with non-intentional weight loss. Both groups will be compared to a Control group consisting of eldery undergoing knee/hip/back surgery but are otherwise considered healthy.

Ages

50 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Lung cancer cachexia: * Diagnosed with NSCLC, stage III-IV * Diagnosed with cachexia (\>5% unintentional body weight loss in past six months, \>2% body weight loss with BMI \<20, or skeletal muscle index for males \<7.26 kg/m2; females \<5.45 kg/m2) * Age 50-60 or 60-70 * Written informed consent Patient group: MIE * Scheduled for total hip, knee, or back surgery * Age 60-70 or 70-80 year * Written informed consent Controls * Patients with scheduled knee-, hip-, and back surgery * Age 50-60, 60-70, and 70-80 year * Age and sex-matched to patient groups * Written informed consent Exclusion Criteria: * No filled-in IC * Suffering from a muscular dystrophy or other disease known to affect muscle morphology or function * Have a weekly alcohol intake of ≥ 35 units (men) or ≥ 24 units (women) * Ongoing participation in other intervention clinical trials * Major surgery of the muscle within 4 weeks of the visit unrelated to the study * Patients unable and/or unwilling to comply with treatment and study instructions * Any other factor that in the opinion of the investigator excludes the patient from the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrophy, muscle are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Cachexia Muscle Weakness muscular atrophy Sarcopenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrophy, muscle Cachexia Mesenchymal stem cells Muscle weakness Sarcopenia Stem cell transplantation

Contacts and locations

Locations

  • Maastricht Universitair Medisch Centrum

    Maastricht, Limburg, 6229HX, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.